N-[(2R)-4-amino-1-[[(2S,3R)-1-[[(2R)-4-amino-1-oxo-1-[[(3S,6S,9S,12R,16R,19S,22R)-6,9,19-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-16-(2-methylpropyl)-2,5,8,11,15,18,21-heptaoxo-12-propan-2-yl-1,4,7,10,14,17,20-heptazacyclotetracos-22-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide

Term ID

CHEBI:94667

Synonyms

Definition

References

LINCS:LSM-5678

Ontology

ChEBI ( EBI )

Relationships

is a type of: peptide

peptide Show first 5 Terms

Phenotype

Phenotype resulting from N-[(2R)-4-amino-1-[[(2S,3R)-1-[[(2R)-4-amino-1-oxo-1-[[(3S,6S,9S,12R,16R,19S,22R)-6,9,19-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-16-(2-methylpropyl)-2,5,8,11,15,18,21-heptaoxo-12-propan-2-yl-1,4,7,10,14,17,20-heptazacyclotetracos-22-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide

Phenotype where environments contain N-[(2R)-4-amino-1-[[(2S,3R)-1-[[(2R)-4-amino-1-oxo-1-[[(3S,6S,9S,12R,16R,19S,22R)-6,9,19-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-16-(2-methylpropyl)-2,5,8,11,15,18,21-heptaoxo-12-propan-2-yl-1,4,7,10,14,17,20-heptazacyclotetracos-22-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide

Phenotype modified by environments containing N-[(2R)-4-amino-1-[[(2S,3R)-1-[[(2R)-4-amino-1-oxo-1-[[(3S,6S,9S,12R,16R,19S,22R)-6,9,19-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-16-(2-methylpropyl)-2,5,8,11,15,18,21-heptaoxo-12-propan-2-yl-1,4,7,10,14,17,20-heptazacyclotetracos-22-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide

Phenotype affecting N-[(2R)-4-amino-1-[[(2S,3R)-1-[[(2R)-4-amino-1-oxo-1-[[(3S,6S,9S,12R,16R,19S,22R)-6,9,19-tris(2-aminoethyl)-3-[(1R)-1-hydroxyethyl]-16-(2-methylpropyl)-2,5,8,11,15,18,21-heptaoxo-12-propan-2-yl-1,4,7,10,14,17,20-heptazacyclotetracos-22-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide

Human Disease Model